» Articles » PMID: 27784628

Advances in Bone Marrow Stem Cell Therapy for Retinal Dysfunction

Overview
Specialty Ophthalmology
Date 2016 Nov 6
PMID 27784628
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The most common cause of untreatable vision loss is dysfunction of the retina. Conditions, such as age-related macular degeneration, diabetic retinopathy and glaucoma remain leading causes of untreatable blindness worldwide. Various stem cell approaches are being explored for treatment of retinal regeneration. The rationale for using bone marrow stem cells to treat retinal dysfunction is based on preclinical evidence showing that bone marrow stem cells can rescue degenerating and ischemic retina. These stem cells have primarily paracrine trophic effects although some cells can directly incorporate into damaged tissue. Since the paracrine trophic effects can have regenerative effects on multiple cells in the retina, the use of this cell therapy is not limited to a particular retinal condition. Autologous bone marrow-derived stem cells are being explored in early clinical trials as therapy for various retinal conditions. These bone marrow stem cells include mesenchymal stem cells, mononuclear cells and CD34 cells. Autologous therapy requires no systemic immunosuppression or donor matching. Intravitreal delivery of CD34 cells and mononuclear cells appears to be tolerated and is being explored since some of these cells can home into the damaged retina after intravitreal administration. The safety of intravitreal delivery of mesenchymal stem cells has not been well established. This review provides an update of the current evidence in support of the use of bone marrow stem cells as treatment for retinal dysfunction. The potential limitations and complications of using certain forms of bone marrow stem cells as therapy are discussed. Future directions of research include methods to optimize the therapeutic potential of these stem cells, non-cellular alternatives using extracellular vesicles, and in vivo high-resolution retinal imaging to detect cellular changes in the retina following cell therapy.

Citing Articles

Future Directions in Diabetic Retinopathy Treatment: Stem Cell Therapy, Nanotechnology, and PPARα Modulation.

Kapa M, Koryciarz I, Kustosik N, Jurowski P, Pniakowska Z J Clin Med. 2025; 14(3).

PMID: 39941353 PMC: 11818668. DOI: 10.3390/jcm14030683.


Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.

Wang L, Huang C, Lin I Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458902 PMC: 11510571. DOI: 10.3390/ph17101261.


Phase I Study of Intravitreal Injection of Autologous CD34+ Stem Cells from Bone Marrow in Eyes with Vision Loss from Retinitis Pigmentosa.

Park S, Bauer G, Fury B, Abedi M, Perotti N, Colead-Bergum D Ophthalmol Sci. 2024; 5(1):100589.

PMID: 39328826 PMC: 11426125. DOI: 10.1016/j.xops.2024.100589.


Progressive Thickening of Retinal Nerve Fiber and Ganglion Cell Complex Layers Following SDM Laser Vision Protection Therapy in Open-Angle Glaucoma.

Luttrull J, Tzekov R, Bhavan S Ophthalmol Ther. 2024; 13(11):2903-2918.

PMID: 39298093 PMC: 11493924. DOI: 10.1007/s40123-024-01029-3.


Stem Leydig cells support macrophage immunological homeostasis through mitochondrial transfer in mice.

Chi A, Yang B, Dai H, Li X, Mo J, Gao Y Nat Commun. 2024; 15(1):2120.

PMID: 38459012 PMC: 10924100. DOI: 10.1038/s41467-024-46190-2.


References
1.
Shaw J, Sicree R, Zimmet P . Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2009; 87(1):4-14. DOI: 10.1016/j.diabres.2009.10.007. View

2.
Anderson J, Johansson H, Graham C, Vesterlund M, Pham M, Bramlett C . Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling. Stem Cells. 2016; 34(3):601-13. PMC: 5785927. DOI: 10.1002/stem.2298. View

3.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

4.
Choi S, Zawadzki R, Lim M, Brandt J, Keltner J, Doble N . Evidence of outer retinal changes in glaucoma patients as revealed by ultrahigh-resolution in vivo retinal imaging. Br J Ophthalmol. 2010; 95(1):131-41. PMC: 3020908. DOI: 10.1136/bjo.2010.183756. View

5.
Fukuda S, Nagano M, Yamashita T, Kimura K, Tsuboi I, Salazar G . Functional endothelial progenitor cells selectively recruit neurovascular protective monocyte-derived F4/80(+) /Ly6c(+) macrophages in a mouse model of retinal degeneration. Stem Cells. 2013; 31(10):2149-61. DOI: 10.1002/stem.1469. View